• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Teva coughs up $519m to settle overseas bribery charges

December 22, 2016 By Sarah Faulkner

Teva coughs up $519m to settle overseas bribery chargesTeva Pharmaceuticals (NYSE:TEVA) will pay $519 million to settle allegations that the company bribed overseas officials in Mexico, Russia and Ukraine to promote its products, according to the U.S. Justice Dept. The department reported that the millions of dollars in bribes occurred for more than a decade.

The pharmaceutical giant agreed to $238 million to settle Foreign Corrupt Practices Act allegations, as well as $236 million in profits plus interest to resolve the Securities and Exchange Commission’s civil investigation.

Teva admitted that it bribed Russian officials and raked in $65 million in inflated, “corrupt” profits, according to Reuters. The company also said that it bribed a Ukrainian government official to gain entrance into the country’s markets.

None of the executives and employees involved in the bribery payments work at Teva anymore, the company said, and it has taken steps since 2012 including naming a global head of compliance.

The company’s improper conduct did not involve any U.S. sales, Reuters reported. The SEC said that Teva must have an independent corporate monitor for at least 3 years.

“As alleged in our complaint, Teva failed to devise and maintain proper internal accounting controls to prevent the company’s payments of bribes to win business in certain regions around the globe,” SEC Enforcement Division deputy director Stephanie Avakian said in prepared remarks.

Filed Under: Featured, Legal News, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Teva Pharmaceuticals

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS